Exact Mass: 504.3199

Exact Mass Matches: 504.3199

Found 63 metabolites which its exact mass value is equals to given mass value 504.3199, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Eudesobovatol A

Eudesobovatol A

C33H44O4 (504.3239)


   

Eudesobovatol B

[2R-(2alpha,4aalpha,8beta,8abeta)]-Decahydro-8-[2-hydroxy-4-(2-propenyl)-6-[4-(2-propenyl)phenoxy]phenoxy]-alpha,alpha,4a,8-tetramethyl-2-naphthalenemethanol

C33H44O4 (504.3239)


   

dipyridamole

dipyridamole

C24H40N8O4 (504.3172)


B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Dipyridamole

2-({6-[bis(2-hydroxyethyl)amino]-4,8-bis(piperidin-1-yl)-[1,3]diazino[5,4-d]pyrimidin-2-yl}(2-hydroxyethyl)amino)ethan-1-ol

C24H40N8O4 (504.3172)


Dipyridamole is only found in individuals that have used or taken this drug. It is a phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation. B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

Rphdhd

3-({3-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]decanoyl}oxy)decanoic acid

C26H48O9 (504.3298)


   

SCHEMBL12225544

SCHEMBL12225544

C26H48O9 (504.3298)


   

(+)-(S)-9-[(Z)-3-(4-methoxyphenyl)prop-2-enoyl]-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadecan-4-one|(+)-(S)-isoverbamekrine|(2S)-9-[(Z)-3-(4-methoxyphenyl)prop-2-enoyl]-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadecan-4-one|(S)-isoverbamekrine

(+)-(S)-9-[(Z)-3-(4-methoxyphenyl)prop-2-enoyl]-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadecan-4-one|(+)-(S)-isoverbamekrine|(2S)-9-[(Z)-3-(4-methoxyphenyl)prop-2-enoyl]-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadecan-4-one|(S)-isoverbamekrine

C30H40N4O3 (504.31)


   

6(S)-(6-O-acetyl-b-D-glucopyranosyloxy)octadecanoic acid

6(S)-(6-O-acetyl-b-D-glucopyranosyloxy)octadecanoic acid

C26H48O9 (504.3298)


   

Dipyridamole (Persantine)

Dipyridamole (Persantine)

C24H40N8O4 (504.3172)


   

3-O-L-rhamnosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid

3-O-alpha-L-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid

C26H48O9 (504.3298)


   

1,6,20,25-Tetraaza[6.1.6.1]paracyclophane

1,6,20,25-Tetraaza[6.1.6.1]paracyclophane

C34H40N4 (504.3253)


   

BIS(4-N,N-DIETHYLAMINOPHENYL)-(4-N-ETHYLAMINONAPHTHALEN-1-YL)ACETONITRILE

BIS(4-N,N-DIETHYLAMINOPHENYL)-(4-N-ETHYLAMINONAPHTHALEN-1-YL)ACETONITRILE

C34H40N4 (504.3253)


   

PENTAERYTHRITOL PROPOXYLATE

PENTAERYTHRITOL PROPOXYLATE

C22H48O12 (504.3146)


   

ZL-Asp(tBu)-OH * DCHA

ZL-Asp(tBu)-OH * DCHA

C28H44N2O6 (504.3199)


   

(1S,2R,3S,4R)-2-((E)-5-(benzyloxy)pent-2-enyl)-3-((tert-butyldimethylsilyloxy)methyl)-4-(tetrahydro-2H-pyran-2-yloxy)cyclopentanol

(1S,2R,3S,4R)-2-((E)-5-(benzyloxy)pent-2-enyl)-3-((tert-butyldimethylsilyloxy)methyl)-4-(tetrahydro-2H-pyran-2-yloxy)cyclopentanol

C29H48O5Si (504.3271)


   
   

(2R,3S)-8-(3-cyclohexylprop-1-ynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

(2R,3S)-8-(3-cyclohexylprop-1-ynyl)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(pyridin-4-ylmethyl)amino]methyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one

C30H40N4O3 (504.31)


   

3-O-alpha-L-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid

3-O-alpha-L-rhamnopyranosyl-3-hydroxydecanoyl-3-hydroxydecanoic acid

C26H48O9 (504.3298)


   

Mgdg O-13:1_4:0

Mgdg O-13:1_4:0

C26H48O9 (504.3298)


   

Mgdg O-14:1_3:0

Mgdg O-14:1_3:0

C26H48O9 (504.3298)


   

Mgdg O-15:1_2:0

Mgdg O-15:1_2:0

C26H48O9 (504.3298)


   

FAHFA 10:3/O-23:7

FAHFA 10:3/O-23:7

C33H44O4 (504.3239)


   

FAHFA 11:3/O-22:7

FAHFA 11:3/O-22:7

C33H44O4 (504.3239)


   

FAHFA 12:3/O-21:7

FAHFA 12:3/O-21:7

C33H44O4 (504.3239)


   

FAHFA 12:4/O-21:6

FAHFA 12:4/O-21:6

C33H44O4 (504.3239)


   

FAHFA 13:4/O-20:6

FAHFA 13:4/O-20:6

C33H44O4 (504.3239)


   

FAHFA 14:4/O-19:6

FAHFA 14:4/O-19:6

C33H44O4 (504.3239)


   

FAHFA 15:4/O-18:6

FAHFA 15:4/O-18:6

C33H44O4 (504.3239)


   

FAHFA 15:5/O-18:5

FAHFA 15:5/O-18:5

C33H44O4 (504.3239)


   

FAHFA 16:5/O-17:5

FAHFA 16:5/O-17:5

C33H44O4 (504.3239)


   

FAHFA 17:5/O-16:5

FAHFA 17:5/O-16:5

C33H44O4 (504.3239)


   

FAHFA 18:5/O-15:5

FAHFA 18:5/O-15:5

C33H44O4 (504.3239)


   

FAHFA 18:6/O-15:4

FAHFA 18:6/O-15:4

C33H44O4 (504.3239)


   

FAHFA 19:6/O-14:4

FAHFA 19:6/O-14:4

C33H44O4 (504.3239)


   

FAHFA 20:6/O-13:4

FAHFA 20:6/O-13:4

C33H44O4 (504.3239)


   

FAHFA 21:6/O-12:4

FAHFA 21:6/O-12:4

C33H44O4 (504.3239)


   

FAHFA 21:7/O-12:3

FAHFA 21:7/O-12:3

C33H44O4 (504.3239)


   

FAHFA 22:7/O-11:3

FAHFA 22:7/O-11:3

C33H44O4 (504.3239)


   

FAHFA 23:7/O-10:3

FAHFA 23:7/O-10:3

C33H44O4 (504.3239)


   

FAHFA 24:7/O-9:3

FAHFA 24:7/O-9:3

C33H44O4 (504.3239)


   

FAHFA 9:3/O-24:7

FAHFA 9:3/O-24:7

C33H44O4 (504.3239)


   
   
   
   

4-hydroxy-6-[(7e,9e,11e)-14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl]-3,5-dimethylpyran-2-one

4-hydroxy-6-[(7e,9e,11e)-14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl]-3,5-dimethylpyran-2-one

C33H44O4 (504.3239)


   

6-({6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl}oxy)octadecanoic acid

6-({6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl}oxy)octadecanoic acid

C26H48O9 (504.3298)


   

(6s)-6-{[(2r,3r,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}octadecanoic acid

(6s)-6-{[(2r,3r,4s,5s,6r)-6-[(acetyloxy)methyl]-3,4,5-trihydroxyoxan-2-yl]oxy}octadecanoic acid

C26H48O9 (504.3298)


   

4-hydroxy-6-(14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl)-3,5-dimethylpyran-2-one

4-hydroxy-6-(14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl)-3,5-dimethylpyran-2-one

C33H44O4 (504.3239)


   

mono-rhamnolipid

mono-rhamnolipid

C26H48O9 (504.3298)


   

(2z)-1-[(8s)-13-acetyl-6-hydroxy-8-phenyl-1,5,9,13-tetraazacycloheptadec-5-en-1-yl]-3-phenylprop-2-en-1-one

(2z)-1-[(8s)-13-acetyl-6-hydroxy-8-phenyl-1,5,9,13-tetraazacycloheptadec-5-en-1-yl]-3-phenylprop-2-en-1-one

C30H40N4O3 (504.31)


   

1-{4-hydroxy-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadec-4-en-9-yl}-3-(4-methoxyphenyl)prop-2-en-1-one

1-{4-hydroxy-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadec-4-en-9-yl}-3-(4-methoxyphenyl)prop-2-en-1-one

C30H40N4O3 (504.31)


   

(2z)-1-[(2s)-4-hydroxy-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadec-4-en-9-yl]-3-(4-methoxyphenyl)prop-2-en-1-one

(2z)-1-[(2s)-4-hydroxy-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadec-4-en-9-yl]-3-(4-methoxyphenyl)prop-2-en-1-one

C30H40N4O3 (504.31)


   

2-{[7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-5-(prop-2-en-1-yl)-3-[4-(prop-2-en-1-yl)phenoxy]phenol

2-{[7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-5-(prop-2-en-1-yl)-3-[4-(prop-2-en-1-yl)phenoxy]phenol

C33H44O4 (504.3239)


   

(2e)-1-[(8s)-13-acetyl-6-hydroxy-8-phenyl-1,5,9,13-tetraazacycloheptadec-5-en-1-yl]-3-phenylprop-2-en-1-one

(2e)-1-[(8s)-13-acetyl-6-hydroxy-8-phenyl-1,5,9,13-tetraazacycloheptadec-5-en-1-yl]-3-phenylprop-2-en-1-one

C30H40N4O3 (504.31)


   

1-(13-acetyl-6-hydroxy-8-phenyl-1,5,9,13-tetraazacycloheptadec-5-en-1-yl)-3-phenylprop-2-en-1-one

1-(13-acetyl-6-hydroxy-8-phenyl-1,5,9,13-tetraazacycloheptadec-5-en-1-yl)-3-phenylprop-2-en-1-one

C30H40N4O3 (504.31)


   

2-{[(1r,4ar,7r,8ar)-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-5-(prop-2-en-1-yl)-3-[4-(prop-2-en-1-yl)phenoxy]phenol

2-{[(1r,4ar,7r,8ar)-7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-5-(prop-2-en-1-yl)-3-[4-(prop-2-en-1-yl)phenoxy]phenol

C33H44O4 (504.3239)


   

4-hydroxy-6-[(1e,7e,9e,11e)-14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl]-3,5-dimethylpyran-2-one

4-hydroxy-6-[(1e,7e,9e,11e)-14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl]-3,5-dimethylpyran-2-one

C33H44O4 (504.3239)


   

(8z)-4-hydroxy-8-[hydroxy(phenyl)methylidene]-4-methyl-1,3,6-tris(3-methylbut-2-en-1-yl)bicyclo[4.3.1]decane-7,10-dione

(8z)-4-hydroxy-8-[hydroxy(phenyl)methylidene]-4-methyl-1,3,6-tris(3-methylbut-2-en-1-yl)bicyclo[4.3.1]decane-7,10-dione

C33H44O4 (504.3239)


   

(2e)-1-[(2s)-4-hydroxy-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadec-4-en-9-yl]-3-(4-methoxyphenyl)prop-2-en-1-one

(2e)-1-[(2s)-4-hydroxy-2-phenyl-1,5,9,14-tetraazabicyclo[12.3.1]octadec-4-en-9-yl]-3-(4-methoxyphenyl)prop-2-en-1-one

C30H40N4O3 (504.31)


   

4-hydroxy-6-[(1e,7e)-14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl]-3,5-dimethylpyran-2-one

4-hydroxy-6-[(1e,7e)-14-hydroxy-9,13,15-trimethyl-17-phenylheptadeca-1,7,9,11-tetraen-1-yl]-3,5-dimethylpyran-2-one

C33H44O4 (504.3239)


   

2-{[7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-4-(prop-2-en-1-yl)-6-[4-(prop-2-en-1-yl)phenoxy]phenol

2-{[7-(2-hydroxypropan-2-yl)-1,4a-dimethyl-octahydronaphthalen-1-yl]oxy}-4-(prop-2-en-1-yl)-6-[4-(prop-2-en-1-yl)phenoxy]phenol

C33H44O4 (504.3239)


   

(3r)-3-{[(3r)-3-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}decanoyl]oxy}decanoic acid

(3r)-3-{[(3r)-3-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}decanoyl]oxy}decanoic acid

C26H48O9 (504.3298)